A carregar...
Immunotherapies based on PD‐1/PD‐L1 pathway inhibitors in ovarian cancer treatment
Immunotherapies based on anti‐programmed death 1/programmed death ligand 1 (PD‐1/PD‐L1) pathway inhibitors may turn out effective in ovarian cancer (OC) treatment. They can be used in combination with standard therapy and are especially promising in recurrent and platinum‐resistant OC. There is grow...
Na minha lista:
| Publicado no: | Clin Exp Immunol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6378380/ https://ncbi.nlm.nih.gov/pubmed/30582756 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cei.13255 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|